docwirenews.com
Cure8 news brief
Mirikizumab Sustains Long-Term Efficacy in Crohn's Disease | AGA - DocWire News
Medications
Mirikizumab
IL-23 inhibitor
Biomarkers
Remission
Phase 3 clinical trial
Adult patients
Clinicians
Why This Matters
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year nonresponders — potentially avoiding a switch to a different drug class.
Who Should Pay Attention
Adults with Crohn’s disease, patients already receiving or considering biologic treatment (especially mirikizumab), gastroenterologists and IBD clinicians, and researchers studying IL-23–targeting therapies.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This report summarizes 2-year (104-week) results from the open-label VIVID-2 extension of the VIVID-1 program testing mirikizumab (an anti–IL-23p19 monoclonal antibody) in moderately to severely active Crohn’s disease.
Among patients who continued mirikizumab, a large proportion who were endoscopic responders at week 52 maintained endoscopic response through week 104; an IV reinduction strategy allowed about 30% of prior endoscopic nonresponders to achieve endoscopic response by week 104.
Clinical remission and corticosteroid-free status were sustained for many patients, and the safety profile during year 2 was consistent with prior experience. Key trial details are drawn from the article abstract and interim VIVID-2 efficacy/safety data; this is an interim open-label extension report rather than a new randomized controlled trial result.
The article cites ClinicalTrials.gov identifier NCT04232553. Considerations for patients: this summarizes trial extension data rather than prescribing guidance.
Individual treatment decisions (including reinduction or continuing therapy) should be made with a treating clinician who can interpret these results in the context of a person’s history, prior therapies, and local approvals.
Keep In Mind
This is an interim analysis from an open-label extension (VIVID-2) of a program that included earlier randomized study VIVID-1. Open-label extension data can show durability and safety over longer follow-up but are subject to selection and retention biases.
The article summarizes outcomes using modified nonresponder imputation and observed-case analyses; it does not replace full peer-reviewed primary publications and guideline recommendations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 3 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 9, 2026, 1:04 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Eli Lilly reports positive data from trial of Omvoh for Crohn's disease
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved ... - PR Newswire
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...